No serious adverse effects reported in phase III trial of Cuban COVID-19 vaccines
After the start of the second stage of the process this Monday, more than 1,200 subjects in Havana received the second dose of Soberana 02, while another 4,000 were injected with Abdala in the provinces of Santiago de Cuba, Granma and Guantánamo.